A TM-Flow test is a noninvasive screening that evaluates your vascular health, nervous system function, and sweat gland activity in a single 10- to 15-minute session. It combines three FDA-cleared technologies into one platform, giving clinicians a snapshot of how well your blood vessels, heart, and small nerve fibers are working. Most people encounter this test at clinics focused on diabetes management, neuropathy, or cardiovascular risk screening.
What the Test Actually Measures
The TM-Flow system runs three distinct assessments back to back, each targeting a different part of your body’s function.
The first is an ankle-brachial index (ABI), which compares the blood pressure in your ankle to the blood pressure in your arm. The ratio between these two numbers reveals whether your peripheral arteries are narrowing. A normal ABI falls between 1.0 and 1.3. Values between 0.91 and 0.99 are considered acceptable but worth watching. Anything below 0.90 indicates some degree of peripheral artery disease, with readings at or below 0.60 classified as severe.
The second component uses photoplethysmography (PPG), a light-based sensor placed on your finger that tracks how blood volume changes with each heartbeat. From this signal, the system extracts your heart rate variability, which reflects how well your autonomic nervous system is regulating your heart. It also evaluates endothelial function, meaning how flexible and responsive the inner lining of your blood vessels is. Stiff, poorly functioning blood vessel walls are an early marker of cardiovascular risk.
The third technology, called SweatC, measures your skin’s electrical response to assess sweat gland activity. Sweat glands are controlled by small nerve fibers, so reduced sweating patterns can signal early nerve damage. The system uses specific voltage thresholds to determine whether your small fibers are functioning normally, showing reduced activity, or displaying signs of small fiber neuropathy.
Who Gets This Test
The TM-Flow is most commonly used for people with type 2 diabetes or those at high risk for it. Diabetes quietly damages both blood vessels and nerves, often before symptoms appear. Cardiovascular autonomic neuropathy, one of the earliest complications of diabetes, can develop within the first year of diagnosis in up to 20% of patients. It frequently causes no obvious symptoms but can lead to serious problems: silent heart attacks, dangerous heart rhythms, drops in blood pressure when standing, and kidney damage.
The Toronto Consensus Panel on Diabetic Neuropathy recommends early autonomic screening for all patients with diabetes precisely because this nerve damage is so often invisible until something goes wrong. The TM-Flow was designed to catch these changes early, when intervention can still make a difference.
Beyond diabetes, the test is useful for anyone whose doctor suspects peripheral artery disease, autonomic dysfunction, or endothelial problems. Clinics also use it to help distinguish between symptoms caused by poor circulation and symptoms caused by nerve damage, since the two can look similar but require different treatment approaches.
What the Experience Is Like
The TM-Flow itself is quick and painless. You sit in a chair while sensors are placed on your fingers and ankles. Blood pressure cuffs measure your arm and ankle pressures for the ABI reading. The finger sensor collects your heart rate variability and vascular data, and the SweatC component applies a mild stimulus to assess your skin’s electrical response. The whole process typically wraps up in 10 to 15 minutes, with no needles, no fasting, and no special preparation.
This is worth distinguishing from a full autonomic function test, which is a more involved procedure that can take 90 minutes to two hours and may include deep breathing exercises, blowing forcefully into a mouthpiece, and being strapped to a table that tilts you from lying flat to nearly upright. The TM-Flow is a screening tool, not a comprehensive autonomic workup. If your TM-Flow results flag a problem, your doctor may order more detailed testing.
How Results Are Categorized
The TM-Flow software generates a report that groups findings into risk levels based on how many markers come back abnormal. For endothelial function, the system checks five markers. One abnormal result suggests early dysfunction. Two or three abnormal results indicate definite endothelial dysfunction, and four or five point to severe dysfunction.
Cardiac autonomic neuropathy follows a similar grading structure. A single abnormal result is enough for an early diagnosis. Two or three abnormal results confirm definite autonomic neuropathy. If orthostatic hypotension (a significant blood pressure drop when you stand up) is also present, severe autonomic neuropathy is suspected.
The ABI and sweat function results use their own numerical cutoffs, as described above. Reports are designed to be easy for clinicians to interpret quickly, with results organized by system so your doctor can see at a glance where the problems are and how serious they might be.
Why It Matters for Early Detection
The real value of the TM-Flow is consolidation. Measuring vascular health, autonomic nerve function, small fiber nerve health, and endothelial function traditionally requires multiple separate tests, often at different appointments. By combining these into one short screening, the system lowers the barrier to catching problems early.
This matters most for conditions where early and late stages look very different. Endothelial dysfunction and arterial stiffness are closely tied to insulin resistance in type 2 diabetes. The combination of high blood sugar, abnormal cholesterol, and chronic inflammation accelerates plaque buildup in arteries through damage to the vessel lining. Catching endothelial dysfunction before it progresses to blockages gives you and your doctor a wider window to adjust medications, lifestyle, or both. The same logic applies to autonomic neuropathy: identifying it at the “one abnormal marker” stage is far more useful than discovering it after a cardiac event.
The TM-Flow system is manufactured by LD Technology, based in Miami, Florida, and its components hold FDA 510(k) clearance. It is a screening tool, not a standalone diagnostic. Abnormal results typically prompt further evaluation or closer monitoring, while normal results offer reassurance that these systems are functioning well at the time of testing.